BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 04/05/2017
Entire Document
 

 

 

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2017

 

 

 

BioLineRx Ltd.

 

(Translation of registrant’s name into English)

 

 

 

2 HaMa’ayan Street
Modi’in 7177871, Israel

 

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F    x Form 40-F    ¨

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

 

Yes    ¨ No    x

 

 

 

   

 

 

Item 8.01 Other Events.

 

BioLineRx Ltd. (the “Company”) announced today that on April 5, 2017 it closed its previously announced underwritten public offering of approximately 33.8 million American Depositary Shares (“ADSs”), each representing one (1) of its ordinary shares, at a public offering price of $0.85 per ADS. The Company received gross proceeds of $28.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioLineRx, which it expects to use to fund a number of clinical trials, including for BL-8040 and AGI-134, and for working capital and general corporate purposes. A copy of the press release announcing the closing of the transaction is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

In connection with the issuance of the ADSs, on March 31, 2017, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell the ADSs to the Underwriters. For a complete description of the terms and conditions of the Underwriting Agreement, please refer to such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.

 

On April 5, 2017, Yigal Arnon & Co. issued its opinion, a copy of which is filed as Exhibit 5.1 to this report, with respect to the legality of the issuance by the Company of the ordinary shares underlying the ADSs sold pursuant to the prospectus and the related prospectus supplement filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on April 3, 2017.

 

On April 5, 2017, Morrison & Foerster LLP issued its opinion, a copy of which is filed as Exhibit 5.2 to this report, with respect to the legality of the sale by the Company of the ADSs sold pursuant to the prospectus and the related prospectus supplement filed by the Company with the SEC on April 3, 2017.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits

 

The following exhibits are filed as part of this report:

 

Exhibit No.   Description of Exhibit
1.1   Underwriting Agreement, dated March 31, 2017
5.1   Opinion of Yigal Arnon & Co., Israeli Counsel to the Company
5.2   Opinion of Morrison & Foerster LLP, U.S. Counsel to the Company
99.1   Press release dated April 5, 2017

 

   

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BioLineRx Ltd.
     
  By:  /s/ Philip Serlin
    Philip Serlin
    Chief Executive Officer

 

Dated: April 5, 2017